Patents by Inventor Laura Rosa Brunet

Laura Rosa Brunet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY
    Publication number: 20220111046
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against CTLA-4, PD-1, PD-L1 and combinations thereof, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: CHARLES AKLE, LAURA ROSA BRUNET
  • Checkpoint inhibitor and a whole cell for use in cancer therapy
    Patent number: 11207405
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against CTLA-4, PD-1, PD-L1 and combinations thereof, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 28, 2021
    Inventors: Charles Akle, Laura Rosa Brunet
  • IMMUNOTHERAPEUTIC AGENT
    Publication number: 20200297680
    Abstract: Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.
    Type: Application
    Filed: March 31, 2020
    Publication date: September 24, 2020
    Inventors: Laura Rosa Brunet, Christopher A. Lowry
  • Immunotherapeutic agent
    Patent number: 10736864
    Abstract: Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: August 11, 2020
    Assignees: IMMODULON THERAPEUTICS LIMITED, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Laura Rosa Brunet, Christopher A. Lowry
  • IMMUNOTHERAPEUTIC AGENT
    Publication number: 20190167623
    Abstract: Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Laura Rosa Brunet, Christopher A. Lowry
  • A CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY
    Publication number: 20180185479
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against CTLA-4, PD-1, PD-L1 and combinations thereof, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Application
    Filed: June 24, 2016
    Publication date: July 5, 2018
    Inventors: CHARLES AKLE, LAURA ROSA BRUNET
  • IMMUNOTHERAPEUTIC AGENT
    Publication number: 20180185317
    Abstract: Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.
    Type: Application
    Filed: December 28, 2017
    Publication date: July 5, 2018
    Inventors: Laura Rosa Brunet, Christopher A. Lowry
  • Immunotherapeutic agent
    Patent number: 7569213
    Abstract: The invention relates to a compound which is an ester of 1,2,3-propanetriol with one or more C11 to C24 fatty acids, wherein at least one fatty acid has at least one double bond. The compound is useful in the treatment of chronic inflammatory disorders.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: August 4, 2009
    Assignee: Stanford Rook Limited
    Inventors: Laura Rosa Brunet, Graham Rook
  • Immunotherapeutic Agent
    Publication number: 20080004341
    Abstract: The invention relates to a compound which is an ester of 1,2,3-propanetriol with one or more C11 to C24 fatty acids, wherein at least one fatty acid has at least one double bond. The compound is useful in the treatment of chronic inflammatory disorders.
    Type: Application
    Filed: November 22, 2005
    Publication date: January 3, 2008
    Inventors: Laura Rosa Brunet, Graham Rook